間質性肺質 - 終於有藥醫 Interstitial lung disease - Drugs available, finally

FDA approves pirfenidone (Esbriet) and nintedanib (Ofev) for IPF

 Diffuse Lung Disease & Interstitial Lung Disease, Policy, Ethics, Education  Add comments

Oct 172014

 

The U.S. FDA approved the first two drugs proven to slow progression of idiopathic pulmonary fibrosis (IPF): pirfenidone (Esbriet by Roche, which bought Intermune) and nintedanib (Ofev by Boehringer Ingelheim) on Wednesday October 15. Both drugs will offer new hope for patients, and new pain to the insurance companies and the government who pay for them.